基于 mRNA 的癌症疫苗：进展与前景

IF 9.1 1区材料科学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Nano Letters Pub Date : 2024-10-07 DOI:10.1021/acs.nanolett.4c0329610.1021/acs.nanolett.4c03296

Lijin Wu, Weicheng Yi, Shiyu Yao, Sitao Xie, Ruizi Peng, Jing Zhang* and Weihong Tan*,

{"title":"基于 mRNA 的癌症疫苗：进展与前景","authors":"Lijin Wu, Weicheng Yi, Shiyu Yao, Sitao Xie, Ruizi Peng, Jing Zhang* and Weihong Tan*, ","doi":"10.1021/acs.nanolett.4c0329610.1021/acs.nanolett.4c03296","DOIUrl":null,"url":null,"abstract":"<p >The success of mRNA COVID-19 vaccines has reinvigorated research and interest in mRNA-based cancer vaccines. Despite promising results in clinical trials, therapeutic mRNA-based cancer vaccines have not yet been approved for human use. These vaccines are designed to trigger tumor regression, establish enduring antitumor memory, and mitigate adverse reactions. However, challenges such as tumor-induced immunosuppression and immunoresistance significantly hinder their application. Here, we provide an overview of the recent advances of neoantigen discovery and delivery systems for mRNA vaccines, focusing on improving clinical efficacy. Additionally, we summarize the recent clinical advances involving mRNA cancer vaccines and discuss prospective strategies for overcoming immuneresistance.</p>","PeriodicalId":53,"journal":{"name":"Nano Letters","volume":"24 41","pages":"12711–12721 12711–12721"},"PeriodicalIF":9.1000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"mRNA-Based Cancer Vaccines: Advancements and Prospects\",\"authors\":\"Lijin Wu, Weicheng Yi, Shiyu Yao, Sitao Xie, Ruizi Peng, Jing Zhang* and Weihong Tan*, \",\"doi\":\"10.1021/acs.nanolett.4c0329610.1021/acs.nanolett.4c03296\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >The success of mRNA COVID-19 vaccines has reinvigorated research and interest in mRNA-based cancer vaccines. Despite promising results in clinical trials, therapeutic mRNA-based cancer vaccines have not yet been approved for human use. These vaccines are designed to trigger tumor regression, establish enduring antitumor memory, and mitigate adverse reactions. However, challenges such as tumor-induced immunosuppression and immunoresistance significantly hinder their application. Here, we provide an overview of the recent advances of neoantigen discovery and delivery systems for mRNA vaccines, focusing on improving clinical efficacy. Additionally, we summarize the recent clinical advances involving mRNA cancer vaccines and discuss prospective strategies for overcoming immuneresistance.</p>\",\"PeriodicalId\":53,\"journal\":{\"name\":\"Nano Letters\",\"volume\":\"24 41\",\"pages\":\"12711–12721 12711–12721\"},\"PeriodicalIF\":9.1000,\"publicationDate\":\"2024-10-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nano Letters\",\"FirstCategoryId\":\"88\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acs.nanolett.4c03296\",\"RegionNum\":1,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nano Letters","FirstCategoryId":"88","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.nanolett.4c03296","RegionNum":1,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

摘要

mRNA COVID-19 疫苗的成功重新激发了人们对基于 mRNA 的癌症疫苗的研究和兴趣。尽管临床试验结果令人鼓舞，但基于 mRNA 的治疗性癌症疫苗尚未获准用于人类。这些疫苗旨在引发肿瘤消退、建立持久的抗肿瘤记忆并减轻不良反应。然而，肿瘤诱导的免疫抑制和免疫阻抗等挑战极大地阻碍了它们的应用。在此，我们概述了 mRNA 疫苗的新抗原发现和递送系统的最新进展，重点是提高临床疗效。此外，我们还总结了涉及 mRNA 癌症疫苗的最新临床进展，并讨论了克服免疫耐受的前瞻性策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

mRNA-Based Cancer Vaccines: Advancements and Prospects

查看原文本刊更多论文

mRNA-Based Cancer Vaccines: Advancements and Prospects

The success of mRNA COVID-19 vaccines has reinvigorated research and interest in mRNA-based cancer vaccines. Despite promising results in clinical trials, therapeutic mRNA-based cancer vaccines have not yet been approved for human use. These vaccines are designed to trigger tumor regression, establish enduring antitumor memory, and mitigate adverse reactions. However, challenges such as tumor-induced immunosuppression and immunoresistance significantly hinder their application. Here, we provide an overview of the recent advances of neoantigen discovery and delivery systems for mRNA vaccines, focusing on improving clinical efficacy. Additionally, we summarize the recent clinical advances involving mRNA cancer vaccines and discuss prospective strategies for overcoming immuneresistance.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nano Letters 工程技术-材料科学：综合

CiteScore

16.80

自引率

2.80%

发文量

1182

审稿时长

1.4 months

期刊介绍： Nano Letters serves as a dynamic platform for promptly disseminating original results in fundamental, applied, and emerging research across all facets of nanoscience and nanotechnology. A pivotal criterion for inclusion within Nano Letters is the convergence of at least two different areas or disciplines, ensuring a rich interdisciplinary scope. The journal is dedicated to fostering exploration in diverse areas, including: - Experimental and theoretical findings on physical, chemical, and biological phenomena at the nanoscale - Synthesis, characterization, and processing of organic, inorganic, polymer, and hybrid nanomaterials through physical, chemical, and biological methodologies - Modeling and simulation of synthetic, assembly, and interaction processes - Realization of integrated nanostructures and nano-engineered devices exhibiting advanced performance - Applications of nanoscale materials in living and environmental systems Nano Letters is committed to advancing and showcasing groundbreaking research that intersects various domains, fostering innovation and collaboration in the ever-evolving field of nanoscience and nanotechnology.